Real-Time Genomic Insights Through Minimally Invasive Cancer Profiling
Liquid biopsy testing at DNA GTx harnesses circulating cell-free DNA (cfDNA) to characterize the dynamic genomic landscape of cancer through a minimally invasive blood draw. This approach enables sensitive detection of clinically relevant somatic variants, offering a powerful tool for therapy selection, treatment monitoring, and assessment of disease evolution over time. By capturing tumor-derived genetic information from the bloodstream, liquid biopsy supports longitudinal cancer management and precision care.
Nos services
Advanced Molecular Profiling to Guide Cancer Care
Liquid biopsy analyzes circulating cell-free DNA (cfDNA) from blood to non-invasively detect tumor-derived alterations. This approach enables real-time monitoring of disease, treatment response, and emerging resistance, offering a practical alternative when tissue biopsy is limited or repeat sampling is needed.
Gain Clarity in Cancer Care:
Reveal Tumor-Specific Mutations
- Detect genetic alterations driving tumor growth, including rare and complex variants.
Guide Targeted Therapies
- Support personalized treatment plans by matching patients to therapies based on their tumor profile.
Monitor Disease Dynamics
- Use liquid biopsy to track treatment response and detect minimal residual disease in real time.
Caractéristiques:
- Covers a wide range of genes associated with cancer-related alterations
- Next-generation sequencing (NGS) for detection of SNVs and indels
- Blood-based testing
- High-sensitivity liquid biopsy for real-time monitoring, minimal residual disease, and therapy resistance
- Clinically actionable reports aligned with ACMG and AMP guidelines
- Matched therapy and clinical trial insights to support precision treatment decisions
Résultats
- Informed treatment selection with targeted therapy and immunotherapy guidance
- Real-time monitoring of treatment response and detection of emerging resistance mutations
- Faster clinical decisions through streamlined reporting and expert interpretation
- Expanded access to clinical trials based on tumor mutation profiling
- Improved patient outcomes through personalized, genomics-guided cancer care
- Support across the cancer continuum, from diagnosis to progression monitoring and recurrence detection
Conçu pour :
- Oncologists
- Pathologists
- Cancer Patients
- Hospitals and Cancer Centers
- Researchers
- Healthcare Systems
Pourquoi choisir
DNA GTx ?
- Integration with multidisciplinary teams: Collaborative approach supporting oncologists, pathologists, and researchers.
- Robust bioinformatics: Advanced algorithms minimize false positives and enhance variant interpretation.
- Comprehensive data security: Ensures patient data confidentiality and compliance with data protection regulations.
- Rapid Sample Processing: Efficient workflows reduce sample handling time and potential degradation.
Oncology Test Panels
Séquençage clinique
Solutions for Researchers
Prise en charge prénatale
Médecine régénérative
Healthcare
Agriculture
Let’s Decode the Future of Health — Together
Get in touch today — let’s start a conversation that could change lives
*All information is handled with strict confidentiality.
Find Answers Today
Early detection saves lives
*All information is handled with strict confidentiality.
